Biogen Idec and MAKScientific Team Up

Boston based MAKScientific and Biogen Idec have entered an agreement valued at up to $34 million to develop cannabinoid modulating drugs for multiple sclerosis and other neurodegenerative diseases. In addition to the well known analgesic effects of cannabinoids, MAKScientific is exploring the neuroprotective activities of cannabinoid signaling, a pathway previously shown to be dysregulated in ALS.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail